Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | FURIN | P09958 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30522774 | 0.98 | PARP10 (0.52) | PARP10FURINEPHX2ALDH1A1TSHR | |
| SCHEMBL2414756 | 0.95 | PARP10 (0.48) | PARP10FURINEPHX2ALDH1A1TSHR | |
| SCHEMBL623713 | 0.93 | PARP10 (0.47) | PARP10FURINEPHX2ALDH1A1TSHR | |
| SCHEMBL835805 | 0.91 | EPHX2 (0.49) | PARP10EPHX2ALDH1A1TSHRMAPT | |
| SCHEMBL23410183 | 0.83 | HRH1 (0.58) | PARP10HRH1HRH3 | |
| SCHEMBL29995412 | 0.83 | HRH1 (0.58) | PARP10HRH1HRH3 | |
| SCHEMBL17962761 | 0.82 | ABL1 (0.46) | PARP10ALDH1A1MAPT | |
| SCHEMBL2016296 | 0.81 | EPHX2 (0.43) | PARP10EPHX2ALDH1A1TSHRMAPT | |
| SCHEMBL1539247 | 0.81 | KDM1A (0.44) | PARP10EPHX2TSHRMAPTHRH1 | |
| SCHEMBL20335443 | 0.81 | EPHX2 (0.43) | PARP10EPHX2ALDH1A1MAPTHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| CN-110520413-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2022133529-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| WO-2018149419-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2018-08-23 | — | — | WO | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | ROTH GERALD JUERGEN (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | ROTH GERALD JUERGEN (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | ROTH GERALD JUERGEN (DE) | 2013-06-06 | — | — | US | disclosed |
| WO-2013079668-A1 | PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079668-A1 | PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | P2RX5, PIR, P2RX4 | PARP10 967/4885FURIN 2410/4885EPHX2 2038/4885 |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | PARP10 1176/4885FURIN 1043/4885EPHX2 1711/4885 |
| US-20130158004-A1 | Azetidine Derivatives | GPR119, LIPE, LPL | PARP10 3995/4885FURIN 4357/4885EPHX2 3228/4885 |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PARP10 1444/4885FURIN 178/4885EPHX2 4758/4885 |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | PARP10 359/4885FURIN 2930/4885EPHX2 3749/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PARP10 1444/4885FURIN 178/4885EPHX2 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.